Portal de Periódicos da CAPES

Comparison of DL-8280 and Amoxicillin in the Treatment of Respiratory Tract Infections

1984; Volume: 58; Issue: 6 Linguagem: Inglês

10.11150/kansenshogakuzasshi1970.58.525

1884-569X

Hiroyuki Kobayashi, Kenji Takamura, Kota KONO, Sokichi Onodera, Nobuhiro Sasaki, Fumio Nagahama, Yoshikazu Kawakami, Yukihiko Honma, M. Matsuzaki, Kazunori Tanimura, Mikio Inoue, Akira Saito, Masumi Tomizawa, Ichiro Nakayama, Yomei HIRAGA, Koki KIKUCHI, Asako Yamamoto, Kazuo Takebe, Tomio Onuma, Toyokazu Tamura, Shuichiro Yoshida, Shigeru OCHIAI, Katsutoshi Kariya, Akiko Yamanaka, Naoyoshi MASAKI, Katsuhiro OKAMOTO, Masao Tamura, Takashi Ito, Yoshikatsu NEMOTO, Seiki Satoh, Shiroh IDA, Tamotsu Takishima, Kiyoshi Konno, Kōtaro Ōizumi, Seiichi Aonuma, Izumi Hayashi, Tatsuya Abe, T Aoyagi, Yuichi Koizumi, Masataka Katsu, Masanori Adachi, Hajimu Takeda, Osamu Sekine, Yoshimaru Usuda, Nobuki Aoki, Isao Nitta, Kyoko Watanabe, Fusanosuke YAMASAKU, Yasutoshi SUZUKI, Atsushi Saitô, Kohya Shiba, Tadashi Miyahara, Keiichi Nakagawa, Kentaro Watanabe, Masaru Koyama, Ko FUKUI, Keimei Mashimo, Yoshiji YAMANE, K Hanaoka, Hiroichi Tanimoto, Yoshitaka Nakamori, Naohiko Chonabayashi, Kunihiko Yoshimura, Ryuo NAKATANI, Koichiro Nakata, Hideo IKEMOTO, Kazuyoshi Watanabe, Kaoru Shimada, Kyoko URAYAMA, Takashi Inamatsu, Yuzo FUNATSU, Fuyuhiko HIGASHI, Takao Takizawa, Jun Tamaoki, Junzaburo Kabe, Hiroyoshi ISHIBASHI, Masako Kato, Toshio Ito, Ippei FUJIMORI, Yoshio Kobayashi, Mitsuo Obana, Shigeki Odagiri, Hirotada Ikeda, Kaneo Suzuki, Kou MUROHASHI, Tamotsu Kaneko, Kazufuto FUKAYA, Fumio Matsumoto, Kaoru OYAMA, Naoki Suzuki, Kaoru Shimokata, Keisuke Nishiwaki, Shūzō Sakai, Masanori Morise, Yasunobu Totani, Masahito Kato, Toshihiko Takeuchi, Hidekazu Hanaki, Saburo Kitaura, Toshiyuki Yamamoto, K Torikai, Yoichi Abe, Nobuo Maekawa, Michiyasu NAKANISHI, Takekuni Iwata, Kazukiyo Oida, Ryoichi Amitani, Yoshiro Mochizuki, Yoshio Taguchi, Nobuo Inaba, Yoshiro Oda, Akira KAGIOKA, Hiroyuki Tsujino, Hitoshi Nakai, Kyosuke Ishihara, Hiroko Sakamoto, Yoko YAMAGATA, Fumio Miki, Kenji TAKAMATSU, Yuruko OKAMOTO, Keigo MAEHARA, Muneto Yoshioka, Yube IIDA, K Yasunaga, Hiroshi Okubo, Y. Ueda, Rinzō Soejima, Yoshito Niki, Chikara Nakahama, Masatoshi Watanabe, Jiro Hino, Osamu Kurimura, Yoshihiko Aratani, Hideo Sasaki, Hirofumi FUKUHARA, Yukio Nishimoto, Michio Yamakido, Keiko Iwamoto, N Kodomari, Eiro Tsubura, Masakazu Tamura, Hidetoshi Ohguchi, Yoshiro Sawae, Kaoru Okada, Yukio Kumagai, Hitoshi Nagano, H Tsurutani, Reiko Kishikawa, Takashi Itoga, Masaru Nasu, Jun Goto, Kohei Hara, Atsushi Saitô, Keizo Yamaguchi, Yoji SUZUYAMA, Yoshiteru SHIGENO, Koichi Watanabe, Masamoto Nakano, Akira Ikebe, Makoto Ishizaki, Tsunetoshi KOTEDA, Keizō Matsumoto, Harumi Shishido, Kunio KUDO, Hisao Kimura, Masayuki Ando, Mineharu Sugimoto, Moritaka Suga, Yasutsugu Fukuda, Katsumasa Tokunaga, H Tokuomi, Kiyoshi Shima, Sadanobu Higuchi, Shinobu Takenaka, Kazumine Kobari, Masao Nakatomi, Yuei Irabu,

Phenothiazines and Benzothiazines Synthesis and Activities

The clinical effectiveness and side effects of DL-8280 in the treatment of lower respiratory tract infections including pneumonias were compared with those of amoxicillin (AMPC) by a double-dummy fashion.The following diseases were included in this study; infectious exacerbation of chronic bronchitis and diffuse panbronchiolitis, chronic respiratory tract diseases with infections (bronchiectasis, bronchial asthma, pulmonary emphysema, lung fibrosis, inactive pulmonary tuberculosis) and various kinds of bacterial pneumonias.Two hundred mg dose of DL-8280 was orally administered 3 times per day and 250 mg dose of AMPC was orally administered 4 times per day. Out of all 279 patients, DL-8280 was used in 139patients and AMPC was in 140 patients. Clinical effectiveness and side effects were observed and the obtained results were as follows.1) One hundred and twenty-two patients of DL-8280 group and 115 patients of AMPC group were evaluated on clinical effectiveness. In DL-8280 group, 6 patients were judgedas “Excellent”, 89 as “Good”, 16 as “Fair”, 10 as “Poor” and its effectiveness rate was 78.5%. On the other hand, in AMPC group, 5 patients were judged as “Excellent”, 73 as “Good”, 14 as “Fair”, 22 as “Poor” and the effectiveness rate was 68.4%. However, one unevaluable patient was seen in each group. The clinical effectiveness of DL-8280 was superior to that of AMPC, especially, the effectiveness rate of DL-8280 group was significantly higher in chronic bronchitis.2) Bacteriologically, the eradication rate of 88.6% was observed out of 79 clinical isolates in DL-8280 group and it was 61.1% in 72 clinical isolates in AMPC group. These results revealed the significant superiority of DL-8280 to AMPC. Particularly, the bacteriological response of DL-8280 against H. influenzae was significantly superior to that of AMPC.3) Side effects were noted in 6.1% of 132 patients with DL-8280 and 7.7% of 130 patients with AMPC, and abnormal changes in laboratory findings were noted in 11.1% in DL-8280 group and 14.2% in AMPC group after administration. There was no significant difference between two groups. Neither progressive side effect nor remarkable change in laboratory findings was noted.4) From these results, it was concluded that DL-8280 was more useful agent than AMPC in the treatment for lower respiratory tract infections, particularly chronic complicated cases.